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Site-selective incorporation and ligation of
protein aldehydes
Richard J. Spears and Martin A. Fascione*
The incorporation of aldehyde handles into proteins, and subsequent chemical reactions thereof, is
rapidly proving to be an eﬀective way of generating homogeneous, covalently linked protein constructs
that can display a vast array of functionality. In this review, we discuss methods for introducing aldehydes
into target proteins, and summarise the ligation strategies for site-selective modiﬁcation of proteins con-
taining this class of functional handles.
I. Introduction
The ability to site-selectively modify proteins with functional
moieties is of major interest within the field of chemical
biology, where the chemical ligation of functional molecules
to proteins can vastly enhance their properties. For example,
conjugation of compounds such as polyethyleneglycol (PEG)
can improve the half-life of protein probes and therapeutics,1
while the ligation of fluorescent/spectroscopic probes has been
utilised for in vivo imaging and tracking of proteins and other
biomolecules.2,3 Additionally, pioneering advances in transla-
tional personalised medicine have been achieved through
chemical ligation strategies, including the construction of
homogeneous antibody-drug conjugates (ADCs) that are
robust, eﬀective, and display selective targeting potential.4
From a cell biology perspective, the ability to functionalise pro-
teins at specific sites also shows particular promise in the
design of new tools for probing post-translational modifi-
cations (PTMs).5
Many chemical protein modification strategies involve reac-
tion of an amino acid side chain, such as the ε-amino group of
a lysine6 and/or the thiol group of a cysteine,7 whilst tyrosine8
and tryptophan9 side chains can also be exploited for chemical
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functionalisation of proteins. All of these methodologies share
one common drawback however, in that site-selectivity cannot
be achieved when more than one of these amino acid side
chains is present within a protein. In recent years more
nuanced protein labelling strategies have emerged; these strat-
egies primarily focus around incorporating a unique func-
tional ‘handle’ into a protein that is not naturally present
within the proteinogenic amino acid side chains. The tagged
protein is then subjected to a substrate that bears a reactive
moiety that specifically reacts only with the handle, and does
not interact with other functional groups, generating homo-
genous protein constructs. Revolutionary examples include
the Staudinger ligation,10,11 azide–alkyne click reactions,12 and
metal mediated metathesis reactions.13 These strategies have
also been utilised in labelling of glycoproteins in complex bio-
logical environments, including live Zebrafish embryos,2,3
without perturbing the native environment; this is known as
‘bioorthogonal chemistry’. A general review covering this
rapidly evolving field has recently been published.14
One functional group not traditionally found within pro-
teins is the aldehyde functionality. This reactive carbonyl
moiety has wide ranging applications in traditional organic
synthesis and can participate in a variety of synthetically
useful reactions, including synthesis of native peptide
bonds.15–17 Aldehydes also feature notably in protein semi-
synthesis protocols, including serine/threonine ligations at
C-terminal salicylaldehyde esters,18,19 and a variant of the
α-ketoacid-hydroxylamine (KAHA) ligation where incorporated
aldehyde side chains can act as purification handles.20 It is
therefore of no surprise that the aldehyde functionality has
seen frequent use within the field of site-selective protein
modification. Upon installation of an aldehyde handle, it is
possible to perform chemistry that reacts with the aldehyde
group to site-selectively label a target protein. Many strategies
exist for the incorporation an aldehyde handle into a desired
protein, along with an increasing selection of ligation protocols
for subsequent site-selective labelling. Of particular note is the
significant number of chemical probes targeting these handles
that are now available commercially. Numerous examples of
aldehyde-based ligations have been reported in the literature,
including synthesis of antibody-drug conjugates (ADCs),
design of proteins bearing PTM ‘mimics’, and labelling of
specific proteins within crude cell lysates (Scheme 1). This
review aims to provide an overview of the strategies currently
reported for incorporating aldehydes into proteins, alongside
reported ligation methods exploited in their subsequent
chemical modification.
II. Incorporating aldehydes into
proteins
A wide variety of strategies can be employed for the incorpo-
ration of aldehyde handles into proteins. It is worth noting at
this point that, although all strategies described incorporate
an aldehyde functionality, the electronic properties of the alde-
hyde installed can vastly diﬀer depending on which strategy is
used. These range from α,β-unsaturated aldehydes to aryl alde-
hydes, as well as electron rich to electron deficient aldehydes.
The tag can also diﬀer in location and distance from the
protein it is attached to. Some of the methods described for
installing aldehyde handles into proteins can also be used to
install ketone handles into proteins; these will be briefly con-
sidered where appropriate.
Oxidation of β amino-alcohols via periodate cleavage
Aldehydes can be installed into proteins via oxidative cleavage
of serine and threonine residues located on the N-terminus of
a protein (Scheme 2).21 This can be achieved through reaction
with sodium periodate (NaIO4) and is analogous to vicinal diol
cleavage (also known as the Malaprade reaction).22 The result-
ing electron-poor N-terminal aldehyde is referred to as an
α-oxo aldehyde or glyoxylamide (or glyoxylylamide). An exten-
sive review on glyoxylamides, along with their carboxylic acid
counterpart (glyoxylic acids), has recently been published.23
Scheme 1 Overview site-selective ligation of an aldehyde handle
incorporated into a generic protein.
Scheme 2 (A) Oxidation of serine/threonine N-terminated proteins to
generate a glyoxylamide (glyoxyl) species. (B) The aldehyde and hydrate
form of the glyoxyl species.
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A particular advantage of generating an aldehyde via this
method is that the reaction is rapid; oxidation of β amino alco-
hols is 100–1000 times faster than the oxidation of vicinal
diols encountered in carbohydrates.24 Care must be taken
when using this method however as other amino acids can be
oxidised under certain conditions (cysteine and methionine
residues in particular).23 Therefore, the reaction is usually per-
formed with or quenched by another component such as
excess methionine or ethylene glycol, followed by purification
of the oxidised protein,25,26 which exists in an equilibrium as a
mixture of aldehyde and hydrate form (Scheme 2B).
N-Terminal oxidation strategies
A biomimetic transamination reaction for the installation of
both aldehydes and ketones into proteins has also been
described in the literature (Scheme 3). An initial screen of alde-
hyde reagents on the peptide angiotensin I identified pyridoxal
5-phosphate (PLP) as a successful reagent for the oxidation of
the N-terminal aspartate residue (generating a ketone) under
mild conditions (pH 6.5 PB, 18 hours, 37 °C). The N-terminal
ketone generated from this biomimetic transformation can
then be site-selectively modified further. PLP-mediated trans-
amination was successfully demonstrated on a number of pro-
teins bearing diﬀerent amino acids at their N-terminus,
including conversion of N-terminal glycine to a glyoxylamide
in horse heart myoglobin, and oxidation of N-terminal lysine
to a ketone in RNAase A.27 The transamination is specific
for the amino group of the N-terminal amino acid, and
does not modify other amine bearing residues such as lysine
side chains. Optimisation of PLP-mediated transamination
has since undergone extensive investigation utilising solid
phase peptide synthesis (SPPS)28 and combinatorial peptide
libraries.29 PLP mediated transamination of resin bound
peptides identified that sequences containing alanine, glycine,
aspartate, glutamate, or glutamine residues at the N-terminus
were transformed into the desired transamination product in
the highest yields. Histidine, lysine, tryptophan and proline
N-termini containing peptides gave rise to PLP-adduct-type
byproducts, whereas isoleucine and valine N-terminated
peptides displayed very poor reactivity in PLP-mediated trans-
amination.28 The observation that the valine N-termini are
unsuitable for transamination is contradictory to the pre-
viously reported successful transamination of valine N-termi-
nal green fluorescent protein (GFP1 V);27 this was rationalised
on the basis that the internal sequence of a peptide/protein
may also aﬀect the success of PLP-mediated transamination.
Additional screening of resin bound lysine and valine
N-terminal tetrapeptides demonstrated that the identity of the
amino acid at position 2 and 3 can dramatically aﬀect the
outcome of the transamination reaction.28 Combinatorial
peptide libraries screens have subsequently revealed that
alanine N-terminated peptides/proteins, directly followed by a
lysine residue, are highly reactive towards PLP-mediated trans-
amination.29 Transamination of short isoleucine, leucine, and
valine N-terminal peptides using another pyridoxal derivative,
along with the eﬀects of using an imidazole-based buﬀer
system on the transamination reaction, have also been recently
reported.30
An alternative reagent for transamination-mediated reac-
tions on proteins has been reported more recently.31 Using
previously described combinatorial peptide libraries,29
N-methylpyridinium-4-carboxaldehyde (Rapoport’s Salt, ‘RS’,
Scheme 3) has since been identified as an eﬀective reagent for
transamination-type modification of proteins; in particular, RS
is highly suitable for glutamate N-terminated peptides/
proteins.31 Optimisation of the transamination using SPPS has
demonstrated that RS is a poor transamination reagent for
glycine, serine, threonine, or proline N-terminated peptides,
but is very suitable for alanine, and glutamate N-terminated
peptides. Additionally, it is worth noting that for all
Scheme 3 (A) Oxidation of the N-terminus using pyridoxal-5-phosphate (PLP) to generate a reactive aldehyde (or ketone). (B) The structure PLP
and Rapoport’s Salt (RS).
Review Organic & Biomolecular Chemistry
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N-terminated amino acids discussed (with the exception of
proline), improved yields of the desired transamination
product were obtained when using RS under more basic con-
ditions (pH 7.5–8.5 as opposed to pH 6.5).32
Genetic incorporation of a formylglycine tag
Alongside the chemical methods described earlier for instal-
ling aldehydes into proteins, enzymatic methods, such as the
formylglycine tag, have also been exploited and reported
(Scheme 4).33 Formylglycine (fGly) is an electron-rich aldehyde
side chain derived from the chemoenzymatic oxidation and
subsequent hydrolysis of a cysteine residue that is located
within a consensus sequence of CxPxR (where x = any amino
acid). Conversion of the thiol to the aldehyde is carried out by
the Formylglycine Generating Enzyme (FGE). In nature, this
transformation is essential for the enzymatic turnover in the
active site of sulfatase enzymes; fGly is the active site residue
that is responsible for the catalytic hydrolysis of sulfate
esters.34 Use of the fGly residue for selective modifications of
proteins was first described in 2007.33 Short tags containing
motifs that are targeted by sulfatases and subjected to fGly
conversion in nature were installed at the N or C-termini of
human growth hormone, mycobacterial sulfotransferase, and
maltose-binding protein. Co-expression of the recombinant
target proteins in E. coli alongside M. tuberculosis FGE resulted
in >85% conversion of the CxPxR-containing proteins to the
desired fGly-tagged proteins (confirmed by MS and subsequent
tryptic digest/modification experiments). The fGly tag has
since been utilised to install monosaccharides35 (which can be
used as glycosyl acceptors to build N-glycans via endoglyco-
synthase enzymatic derivatisation),36 biotinylated probes,37
and therapeutically relevant small molecules.37–40 The fGly
handle has also been used in the specific labelling of tagged
proteins in cell extracts.41 In addition to prokaryotic cell lines,
this methodology has also been utilised successfully in mam-
malian expression systems.42 Investigation into preactivation of
FGE to improve turnover rates using copper has also been
reported.43 For a more detailed discussion on FGEs and the fGly
motif, readers are directed to a recent review in the field.44
Enzymatic incorporation of farnesyl pyrophosphate analogues
Protein farnesyl-transferase (PFTase) is an enzyme that cata-
lyses the farnesylation of thiol side chains of cysteine residues
in proteins. PFTase utilises farnesyl pyrophosphate (FPP) for
this transformation and is specific for cysteine residues within
a tetrapeptide domain at the C-terminus of a peptide/protein.
This tetrapeptide domain is commonly referred to as a CAAX-
box, where A = aliphatic amino acid, and X = alanine, serine,
methionine, or valine (usually cysteine-valine-isoleucine-
alanine).45,46 Along with its natural substrate FPP, PFTase can
also incorporate FPP analogues such as farnesyl aldehyde pyro-
phosphate (FAPP), allowing for installation of an α,β-unsatu-
rated aldehyde tag into proteins bearing a CAAX-box motif
(Scheme 5A).47 FAPP installation has been demonstrated on
N-dansyl peptides and CAAX-box tagged GFP. Following alde-
hyde installation, tagged proteins can then be specifically iso-
lated via modification of the installed aldehyde.48
PFTase strategies for aldehyde tag incorporation have since
been extended to incorporation of an aryl aldehyde analogue
(Scheme 5B),48 and modification of other proteins such as
ciliary neurotrophic factor protein (CNTF).49 Other aryl alde-
hyde handles that bear alkyne functionality can also be
incorporated using PFTase, allowing for selective, dual
functionalisation of GFP.49 Mutant variants of PFTase have
also been explored in a desire to improve catalytic eﬃciency of
FPP aldehyde analogues; a 43 fold increase, for example, is
observed for the incorporation of aryl aldehyde FPP into
Scheme 4 (A) Outline of generating the formylglycine (fGly) residue on
peptide/proteins bearing a cysteine within a CxPxR sequence. (B)
Expression of a plasmid encoding for the desired protein containing the
CxPxR sequence, followed by treatment with the formylglycine generat-
ing enzyme (FGE) leads to fGly-proteins.
Scheme 5 (A) Protein farnesyl-transferase (PFTase) mediated installa-
tion of farnesyl-derived aldehydes into a protein bearing a C-terminal
CAAX box. (B) Aldehyde analogues that can be incorporated.
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CAAX-box-bearing CNTF when using a W102A β subunit
PFTase variant (as opposed to using wild type PFTase).50
Enzymatic incorporation using lipoic acid ligase
In Escherichia coli, lipoic acid ligase (LplA) is responsible for
linking lipoic acid to various proteins involved in oxidative
metabolism.51 LplA specifically targets lysine side chains
located within a GFEIDK̲VWYDLDA sequence known as the
LplA acceptor peptide (LAP). The incorporation of aldehyde
tags utilising this enzymatic strategy has recently been
described (Scheme 6). W37I mutants of LplA could be used to
incorporate aryl aldehydes into a LAP peptide in a 500 : 150 : 1
ratio of lipoic acid-analogue : LAP-peptide : LplA, with a
maximum of 62% conversion to the aldehyde-tagged LAP
peptide observed after 5 minutes of incubation. Additionally,
proteins bearing LAP tags at the N-terminus, including LAP-
tagged streptavidin and LAP-tagged alkaline phosphatase, were
also successfully modified.52 More recently, this methodology
has been extended to the labelling of LAP-tagged nanobodies.53
Enzymatic incorporation of 3-formyl-L-tyrosine
A very recently described chemoenzymatic method for installa-
tion of aldehyde tags into proteins is through enzymatic trans-
formation using tubulin tyrosine ligase (TTL, Scheme 7).54
Although the natural function of TTL is to post-translationally
modify the C-terminus of α-tubulin with tyrosine, TTL can also
accept tyrosine analogues, such as 3-formyl-L-tyrosine (denoted
as ‘3ForTyr’ in this review), in ligation of C-terminal peptides/
proteins bearing a VDSVEGEGEEEGEE tag (known as a Tub
tag). Mixing of Tub-tagged peptides with TTL in a 200 : 1 ratio
aﬀorded a 63% incorporation of 3ForTyr after 2 hours (moni-
tored by HPLC, with >90% incorporation observed after
6 hours). This methodology has also been utilised in the
tagging of Tub-tagged GFP, ubiquitin, and GFP-specific nano-
bodies. Incubation of TTL : Tub-tagged-protein in an optimal
ratio of 1 : 5 for 3 hours at 37 °C gave rise to successful label-
ling with 3ForTyr (confirmed by tryptic digestion experiments).
Conversions of 99% were achieved under these conditions
(based on SDS-PAGE analysis and observations of other in-
corporated tyrosine analogues).54
Genetic incorporation of non-native aldehyde containing
amino acids
Briefly, another well-publicised strategy55,56 for installing an
aldehyde (or ketone) tag into a protein is to utilise the ever-
increasing number of evolved tRNA/tRNA synthetase pairs to
perform unnatural amino acid mutagenesis (Scheme 8).57–60
The aldehyde (ketone) side chain can then be modified with a
range of functional handles, including fluorescent
probes,57,60,61 biotinylated probes,57,58,61 and carbohydrates.62
ADCs have also recently been developed utilising this
methodology.63,64
III. Chemical strategies for the
modiﬁcation of proteins bearing
aldehyde handles
There now exist a plethora of strategies for the site-selective
modification of proteins following installation of one of the
Scheme 6 (A) Outline of using Lipoic acid ligase (LplA) mutants for
installing aldehydes into LplA accepter peptide (LAP) bearing proteins.
(B) Amino acid sequence of the LAP. (C) Structure of the incorporated
aldehyde.
Scheme 7 (A) Outline of using Tubulin Tyrosine Ligase (TTL) to for the
incorporation of 3-formyl-L-tyrosine (3ForTyr) into proteins bearing a
‘Tub Tag’. (B) The amino acid sequence of the Tub Tag. (C) Structure of
the incorporated 3ForTyr.
Scheme 8 Installation of aldehyde into proteins via unnatural amino
acid mutagenesis. Expression of a plasmid encoding for the desired
protein containing an amber STOP codon in conjunction with an
orthogonal tRNA synthetase/tRNA pair and unnatural amino acid allows
for incorporation of an aldehyde-containing amino acid at the afore-
mentioned STOP position.
Review Organic & Biomolecular Chemistry
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aforementioned aldehyde tags. These range from CvN bond
formation to C–C bond formation, and from metal mediated
ligations to intramolecular cyclisation ligations. The choice of
aldehyde handle, along with the conditions for aldehyde modi-
fication (such as pH or use of additional co-solvent) ranges
from strategy to strategy. The rate of ligation has also been pro-
filed for the majority of strategies described; often using small
molecule aldehydes mimics and, on some occasions, proteins
bearing an aldehyde handle. Selected rate constants (and the
conditions used) for each ligation strategy discussed herein
can be found in Table 1.
Hydrazone/oxime ligations
The reaction of hydrazine and hydroxylamine/aminooxy
reagents with proteins bearing aldehydes (or ketones) to form
hydrazone and oxime bonds, respectively, are among the best
established methods for generating homogenous ligation pro-
ducts (Scheme 9A and B). These ligation strategies proceed via
an iminium-type intermediate, and are by far the most
popular method of modifying aldehydes installed into pro-
teins. Indeed, a standard method for validating installation of
an aldehyde handle into a protein is to perform hydrazone or
oxime ligation with small molecule substrates, and then
analyse the anticipated ligation product by protein mass
spectrometry (protein MS).21,27,31,33,48,57 Uniquely, to date, they
are the only ligation strategies reported in literature that have
been demonstrated on all aldehyde handles that can be incor-
porated into proteins (Scheme 9C, Table 1, entries 1–7). More
complex, functionalised hydrazine/hydroxylamine reagents are
frequently employed for the purpose of protein bioconjuga-
tions. For example, labelling with hydrazine/hydroxylamine
functionalised biotin facilitates isolation of the modified
protein via binding with streptavidin.33,61,80 Use of aminooxy
functionalised resins can also be applied to isolate aldehyde-
tagged proteins via oxime ligation from crude cell lysates.47,48
Successful incorporation of an aldehyde handle into a
protein is also frequently showcased through the reaction
with hydrazine or hydroxylamine functionalised fluorescent
probes.27,31,52,54,60 Analysis of these ligation products via SDS
PAGE analysis with fluorescence emission scanning can be
used to determine the level of success of the initial aldehyde
incorporation method.36 In a similar manner, hydroxylamine
functionalised PEG reagents can also be used to label in-
corporated aldehyde handles; these ligation products can then be
visualised via SDS PAGE analysis.28,32,49,81 As discussed earlier,
carbohydrates have also been installed into proteins via oxime
ligation.35,36,62 In an alternate approach, glycosylated proteins
have also been modified by initial oxidative cleavage of carbo-
hydrate diols with NaIO4, followed by hydrazone ligation of the
resultant aldehyde.82,83 Oxime linked ADCs have also been
reported;53,84 these constructs display both in vitro63 and
in vivo81 cytotoxicity. More unconventional uses of oxime liga-
tions strategies involve linking protein species together for the
design of new therapeutics.26,85 A review on oxime chemistry
within the field of aldehyde handle labelling has very recently
been published.86
Hydrazone and oxime ligations are undoubtedly the most
frequently used method for modifying protein aldehyde/
ketone handles; indeed, the aforementioned commercially avail-
able probes for modifying aldehyde handles are all hydrazine
and hydroxylamine-based. However, these strategies are not
without their drawbacks. Both ligation strategies result in for-
mation of a CvN bond between protein and substrate, and
thus both are susceptible to hydrolysis over time. Of the two,
oxime bonds display greater hydrolytic stability.87 Reductive
amination of hydrazone bonds using sodium cyanoboro-
hydride to form a more stable amine bond can be employed;
however, this strategy is not commonly used within the context
of modifying protein aldehydes (sodium cyanoborohydride is a
water sensitive reagent and its use can lead to undesirable
reduction of disulfide bonds88). Additionally, the optimal pH
for hydrazone and oxime ligations is pH 4.5, with poor reactiv-
ity observed at neutral pH, typically displaying rate constants
of 10−3 M−1 s−1.70,89 To address this, several catalysts for per-
forming hydrazone and oxime ligation at neutral pH have been
investigated; aniline in particular has received a great deal of
attention in the area of hydrazone/oxime ligation catalysis. For
hydrazone ligations of peptide substrates in 10 mM anilinium
buﬀer, a 20 fold increase in ligation rate is observed at pH 4.5,
and a 70 fold increase in ligation rate is observed at pH 5.7
(Table 1, entry 1).65 Similarly, for oxime ligations of peptide
substrates in 100 mM anilinium buﬀer solutions, a 400 fold
increase in ligation rate is observed at pH 4.5, and a 40 fold
increase in ligation rate is observed at pH 7.0.68 Ligations
between aryl aldehydes and 6-hydrazinopyridyl reagents are of
particular note, displaying rate constants within the range of
102–103 M−1 s−1 (Table 1, entry 3).67 The use of aniline in
protein bioconjugation at a neutral pH has subsequently been
reported.26,60 Other aniline-based catalysts have also been
reported, with meta-substituted anilines (Table 1, entry 5)69
and para-substituted anilines (Table 1, entry 6). displaying
improved kinetics to that of aniline for oxime ligations at pH
7.0.70 In all cases, the catalysis is hypothesised to proceed via a
‘transimination’ type mechanism.68 In very particular cases,
aniline does not appear to improve conjugation yields of
oxime ligations.85 Additionally, it has been reported that
typical concentrations of aniline used in oxime ligation strat-
egies (i.e. 100 mM aniline)26,68 exhibit toxicity in live cell label-
ling experiments.60 Other catalysts include boronic acids90 and
2-aminophenols/2-(aminomethyl)benzimidazoles.91
Pictet-Spengler
The cyclisation reaction between tryptamines and aldehydes is
known as the Pictet-Spengler reaction. Formation of the Pictet-
Spengler product occurs through initial iminium formation
between the tryptamine amine and aldehyde, followed by
intramolecular cyclisation. In the context of protein modifi-
cation, an N-terminal Pictet-Spengler ligation on myoglobin
has been reported (Scheme 10A, Table 1, entry 8).72 Following
transamination with PLP,27 the Pictet-Spengler ligation
between glyoxylamide-containing myoglobin (glyoxyl-
myoglobin), and tryptamine, tryptophan methyl ester, and
Organic & Biomolecular Chemistry Review
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Table 1 Comparison of selected rate constants for strategies used in the modiﬁcation of aldehydes under various conditions
Entry Reaction Conditions Rate (M−1 s−1) Ref.
1 1 mM aldehyde 0.0031 (uncatalysed) 65
1 mM hydrazine 0.21 (10 mM aniline)
pH 5.7, NH4OAc
2 1 mM aldehyde 0.0013 (uncatalysed) 66
18 µM hydrazine 0.11 (1 mM 5-methoxyanthralic
acid)
pH 7.4, PBS (10% DMF)
3 10 µM aldehyde 170 (100 mM aniline) 67
10 µM hydrazine
pH 7.0, PB
4 1 mM aldehyde 0.057 (pH 4.5, uncatalysed) 68
1 mM aminooxy 0.68 (pH 4.5, 10 mM aniline)
pH 4.5, NH4OAc
or pH 7.0, PB
0.015 (pH 7.0, uncatalysed)
0.061 (pH 7.0, 100 mM
p-methoxyaniline)
5 50 µM aldehyde 24 (25 mM aniline) 69
100 µM aminooxy 41 (25 mM
m-phenylenediamine)
pH 7.0, PB
6 91 µM aldehyde 0.22 (pH 4.0, uncatalysed) 70
455 µM aminooxy 4.3 (pH 4.0, 10 mM
p-phenylenediamine)
pH 4.0, Na citrate
or pH 7.0, PB
0.006 (pH 7.0, uncatalysed)
0.29 (pH 7.0, 10 mM
p-phenylenediamine)
7 10 mM aldehyde 0.0013 71
10 mM aminooxy
pH 7.0, PB : MeOH (1 : 1)
8 60 µM aldehyde N/Aa 72
50 mM indole
pH 6.5, PB
9 500 µM aldehyde 10.6 (pH 4.5) 37
500 µM indole 0.26 (pH 7.0)
pH 4.5, NaOAc
or pH 7.0, PB
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Table 1 (Contd.)
Entry Reaction Conditions Rate (M−1 s−1) Ref.
10 2.5 mM aldehyde 0.015 71
2.5 mM aldehyde
pH 4, NaOAc : MeOH (1 : 1)
11 50 µM aldehyde 4.2 38
50 µM indole
pH 6, PB
12 300 µM nitrone 12.8 73
330 µM alkyne
H2O :MeCN (9 : 1)
13 1 : 100 molar ratios
(nitrone : alkyne)
58.8 74
MeCN
14 200 µM aldehyde 24 hours, 55% yield (obtained)b 75
400 µM silyl ketene acetal
pH 7.0, PB
15 37.5 µM 5 hours, 90% (conversion)c 75
7.13 mM silyl ketene acetal
H2O : t-BuOH (5 : 1)
16 21 mM aldehyde 16 hours, 56% yield (obtained)b 76
42 mM indium
63 mM allyl bromide
PB pH 7.0
17 37.5 µM aldehyde 20 hours, 54% (conversion)c 76
29 mM indium
836 µM allyl bromide
H2O : t-BuOH (6 : 4)
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Table 1 (Contd.)
Entry Reaction Conditions Rate (M−1 s−1) Ref.
18 10 mM aldehyde 90 min, 67% yield (obtained)b 77
20 mM ylide
H2O : t-BuOH (1 : 1)
19 15 µM aldehyde 30 min, 65% (conversion)c 77
750 µM ylide
H2O : t-BuOH (3 : 1)
20 15 mM aldehyde 0.0086 78
3 mM
2-aminobenzamidoxime
pH 4.5, NaOAc
21 2 mM aldehyde 1 78
1 mM 2-amino
benzamidooxime
pH 4.5, NaOAC
22 2 mM aldehyde 40 78
1 mM 2-amino
benzamidooxime
pH 4.5, NaOAC
23 10 mM aldehyde 0.0078 79
10 mM thiazolidinedione
pH 7.0, PB (25% DMSO)
24 37.5 µM aldehyde 3 hours, 83% (conversion)c 79
37.5 mM thiazolidinedione
pH 7.0, PB
25 25 µM aldehyde 0.387 40
1 mM thiopyrazolone
pH 7.0, Na citrate
aNo rate/yield/conversion given. bNo rate studies performed, reaction time and obtained yield quoted as an alternative. cNo rate studies per-
formed, reaction time and conversion as judged by LC-MS quoted as an alternative.
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tryptamine-functionalised-biotin was successfully carried out
at pH 6.5 (confirmed by MS and subsequent proteolytic digest
experiments), leading to protein constructs ligated to sub-
strates via a C–C bond.72
A variation of the Pictet-Spengler ligation, known as the iso-
Pictet-Spengler ligation, has recently been reported for chemi-
cal modification of aldehyde handles incorporated into pro-
teins (Scheme 10B).37 Analysis of the reaction kinetics of the
traditional Pictet-Spengler ligation was used as the basis for
the design of the iso-Pictet-Spengler ligation. Aminooxy-func-
tionalised indoles (as opposed to tryptamines) were utilised to
accelerate the initial iminium formation between the indole
and the aldehyde tag. Additionally, the aminooxy side chain
was located on the 2-position of the indole ring (as opposed to
the 3 position which is the case for tryptamine reagents) to
accelerate the final cyclisation step. Based on an isobutyr-
aldehyde system (Table 1, entry 9), the optimal pH for the reac-
tion was found to be pH 4.5 (rate constant of 10.6 M−1 s−1),
although product formation is still observed at pH 6.0–7.0
(observed rate constants of 0.76 M−1 s−1 at pH 6.0 and
Scheme 9 (A) Outline of hydrazone ligation on a generic protein
bearing an aldehyde handle. (B) Outline of oxime ligation. (C). Structure
of hydrazone/oxime bond on aldehyde handles that can be incorporated
into proteins.
Scheme 10 (A) The Pictet-Spengler ligation on glyoxyl-myoglobin. (B)
The iso-Pictet Spengler ligation on fGly-tagged maltose binding protein.
(C). The Hydrainzo-iso-Pictet Spengler ligation on an fGly-tagged anti-
body. (D). The Pictet Spengler (left) and iso-Pictet/Hydrazino-iso-Pictet
Spengler ligation at a glyoxyl handle. (E). The iso-Picet Spengler/Hydra-
zino-iso-Pictet Spengler ligation at an fGly handle.
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0.26 M−1 s−1 at pH 7.0).37 For glyoxyl systems, reduced rate
constants for the iso-Pictet Spengler ligation have since been
reported (Table 1, entry 10).71 The use of an aniline catalyst
had no eﬀect on the rate of reaction (and was noted to be
inhibitory at pH 5.0–6.5). Iso-Pictet-Spengler ligations with
PEGylated, biotinylated, and fluorescent probes were success-
fully demonstrated on glyoxyl-myoglobin, fGly-tagged maltose
binding protein (MBP), and fGly-tagged Herceptin anti-
bodies.37 Compared to the original Pictet-Spengler ligation,72
both reagent concentrations and reaction time are vastly
reduced in the iso-Pictet-Spengler ligation.37
A minor alteration to the iso-Pictet-Spengler ligation, known
as the Hydrazino-iso-Pictet-Spengler (HIPS) ligation, has also
been described in the literature (Scheme 10C).38 The concept
of the ligation strategy is nearly identical to that of the iso-
Pictet-Spengler ligation – except an N-methyl hydrazine-func-
tionalised indole is used instead of an aminooxy functiona-
lised indole. This facilitates the ligation at a higher pH of 6.0
(as hydrazines are more reactive than aminooxy compounds at
a higher pH).92 The HIPS ligation shows improved ligation
kinetics to that of the iso-Pictet-Spengler ligation at pH 6.0
(observed rate constants of 4.2 M−1 s−1 using a benzyl-
oxyacetaldehyde system, Table 1, entry 11), and has sub-
sequently been utilised in the synthesis of ADCs.39
Strain-promoted alkyne-nitrone cycloaddition
Alkyne reagents are frequently employed in strategies to selec-
tively modify proteins.93 Typically, an azide handle is installed
into a protein, and then subsequently reacted with the alkyne
species to give the corresponding triazole in a click reaction.
Reactions can be performed either using standard alkyne com-
pounds with a copper catalyst, or can be performed without a
catalyst by using strained alkyne systems such as cyclooctyne
in a ‘strain promoted’ reaction (known as the Strain-Promoted
Azide–Alkyne Cycloaddition, or SPAAC, ligation).12 The latter is
more applicable to biological systems, since it does not require
the use of copper which exhibits cytotoxicity in cells at high
concentrations. Alkyne mediated ligation strategies are com-
monly utilised in metabolic labelling experiments due to their
bioorthogonality.3
Alkynes can also be used to site-selectively modify glyoxyl-
proteins via the Strain-Promoted Alkyne-Nitrone Cycloaddition
(SPANC) ligation (Scheme 11). The SPANC ligation is a one-pot
modification strategy that involves formation of a nitrone
species between the aldehyde and N-methylhydroxylamine, fol-
lowed by a cycloaddition reaction between the nitrone and
strained cyclooctyne (see Table 1, entries 12 and 13 for
examples with small molecules).73 The addition of p-anisidine
greatly enhances the rate of the SPANC ligation – presumably
by a mechanism that is akin to catalysis of hydrazone and
oxime ligations. The SPANC ligation is usually performed at
pH 6.8 (NH4OAc buﬀer) and has been used to site-selectively
modify the oxidised chemokine interleukin 8 (glyoxyl-IL-8)
with a 2 kDa PEG unit.73 Dual functionalisation of glyoxyl-pep-
tides/proteins incorporating both azide–alkyne click chemistry
and the SPANC ligation has also been reported.94 Additionally,
SPANC ligation has been utilised in the design of antibody-
nanoparticle constructs to design multivalent nanoparticles
(MNPs) using N-terminal serine variant of an anti-HER2 scFv
antibody; these MNPs can then be used to selectively, fluores-
cently label HER2 membrane receptors in breast cancer cells.95
A variation of the SPANC ligation using preformed nitrones
has also been utilised in metabolic labelling of live cells
(although these nitrones are susceptible to hydrolysis in
aqueous systems).96 Preformed nitrones have also been the
subject of various kinetic studies, identifying biaryl-aza-cyclo-
ctyne73 and acyclic nitrones systems74 as yielding the highest
rate constants for the SPANC (58.8 M−1 s−1). A review for the
SPANC ligation has recently been published.97
Mukaiyama aldol
The Mukaiyama aldol reaction involves the reaction of an alde-
hyde group and silyl enol ether to give β-hydroxy ketone pro-
ducts. The reaction forms a C–C bond between the aldehyde
and silyl enol ether, is catalysed by Lewis acids (such as TiCl4)
and can be performed in aqueous solvent systems (see ref. 98
for a review on the subject). A Mukaiyama aldol ligation for
peptide and protein modification was first reported in 2010
(Scheme 12).75 Glyoxyl-peptides were functionalised with
various silyl enol ethers in aqueous conditions to aﬀord the
anticipated Mukaiyama aldol ligation products after 24 hours
(see Table 1, entry 14 for an example). Products bearing alkene
functionality could then be modified further by cross meta-
Scheme 11 (A) Glyoxyl-interleukin 8, and formation of a nitrone
species. (B) Reaction of an alkyne with the pre-formed nitrone via a
cycloaddition.
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thesis using a Hoveyda-Grubbs second generation catalyst. The
Mukaiyama aldol ligation has been utilised to modify glyoxyl-
myoglobin, with a maximum of 90% conversion observed as
( judged by LC-MS) in a H2O : t-BuOH (5 : 1) solvent system
(Table 1, entry 15). Choice of solvent system for the
Mukaiyama aldol ligation is of particular importance; 1 : 1
systems such as H2O : t-BuOH, pH 7 PB : EtOH, and
H2O : MeCN all lead to homogenous product formation
(76–90% conversion as judged by LC-MS), whereas other
solvent systems such as H2O : glycerol and H2O : etheylene
glycol lead to no observed conversion to the Mukaiyama aldol
ligation product, or solvent systems such as pH 7 PB : EtOH
(4 : 1), pH 7 PB : t-BuOH (1 : 1), and H2O : t-BuOH (6 : 1) lead to
heterogeneous product mixtures. UV-vis analysis and circular
dichroism (CD) analysis of unmodified and modified myo-
globin samples confirmed that the tertiary structure of the
protein was unaﬀected by the Mukaiyama aldol ligation.75
Indium mediated allylation
An indium mediated allylation within the context of modifying
glyoxyl peptides and proteins with simple allyl bromides has
also recently been reported (Scheme 13).76 Glyoxyl-peptides
were modified by indium mediated allylation with a number
of allyl bromides to give racemic mixtures of the desired pro-
ducts after 18 hours (Table 1, entry 16). The ligation results in
formation of a C–C bond and has also been demonstrated on
glyoxyl-myoglobin, aﬀording a maximum of 54% conversion
after 20 hours to the desired product ( judged by LC-MS analy-
sis, Table 1, entry 17). A 6 : 4 H2O : t-BuOH solvent system and
sonication of the reaction mixture was utilised to achieve con-
version to the desired product (these conditions cause partial
dissociation of the haem group of myoglobin, although it is
possible to reconstitute the protein following modification).76
Wittig
The Wittig reaction, first reported in 1954, is the reaction
between aldehydes and ylide-type reagents to give alkene
products.99 Modification of glyoxyl peptides and proteins
via a Wittig ligation have been recently demonstrated
(Scheme 14).77 Glyoxyl-peptides were successfully modified
with a number of small molecule ylides in a 1 : 1 H2O : t-BuOH
solvent system, generating geometric isomers of the desired
Wittig products (see Table 1, entry 18 for an example). Glyoxyl-
myoglobin and glyoxyl-IL-8 were also modified using this
chemistry in a 3 : 1 H2O : t-BuOH solvent system. The ligation
can also be performed in pH 7–10 buﬀer : t-BuOH systems, but
does not occur in buﬀer systems below pH 6. The Wittig lig-
ation results in formation of a C–C bond, and gives a 65% con-
version complete within 30 minutes on glyoxyl-myoglobin
( judged by LC-MS analysis), (Table 1, entry 19). UV-vis analy-
sis, CD analysis, and analysis of the proteins ability to store
and release oxygen were performed on unmodified and modi-
fied myoglobin samples, confirming that the tertiary structure
of the protein was unaﬀected.77 Other applications of Wittig
olefinations within a bioorthogonal context include the label-
ing of the FK506 macrolide in aqueous media with biotin and
fluorophores (the modified macrolide can then be used to
label F506-binding protein FKBP12 with biotin and fluoro-
phores),100 and the synthesis of alkenes in living tissue.101
2-Amino benzamidoxime
The use of 2-amino benzamidoxime (ABAO) compounds in the
modification of peptides and proteins bearing aldehyde
handles has been very recently described (Scheme 15).78 Initial
screening of a variety of substituted aniline compounds
against model glyoxyl substrates identified ABAO compounds
as suitable reagents for site-selective modification, giving rise
to single, hydrolytically stable dihydroquinazoline products
which exhibit fluorescence at 490 nm. The ligation is per-
formed under acidic conditions (pH 4.5), and is thought to
proceed through via imine formation between the aldehyde
substrate and aniline component. This is followed by intra-
molecular cyclisation via attack of the ABAO ortho amidoxime
group at the newly formed imine, completing the ligation. The
rate of ABAO ligation can vary depending on the both the
Scheme 13 Outline an indium mediated allylation of glyoxyl-
myoglobin.
Scheme 14 Outline of Wittig ligation of glyoxyl-interleukin 8.
Scheme 12 Outline of a Mukaiyama ligation on glyoxyl-myoglobin.
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choice of aldehyde and ABAO derivative; in particular, higher
rate constants are observed in isobutyraldehyde systems com-
pared to glyoxyl systems (40 M−1 s−1 compared to 1 M−1 s−1,
Table 1, entries 21 and 22), and also in para-methoxy ABAO
systems (Table 1, entry 20). Acetate (from the NaOAc buﬀer)
can also act as a weak catalyst in the ABAO ligation (as
observed from altering buﬀer concentrations). Notably, ABAO
ligation is slow when the aldehyde substrate in question is
glucose (in a ring opened form), suggesting that ABAO ligation
could be expanded to other selective labelling applications in
more complex biological mixtures. The ABAO ligation has been
used in the biotinylation of horseradish peroxidase (HRP)
bearing aldehydes derived from oxidised glycans, and
additionally in the biotinylation of glyoxyl-peptide bearing
M13 phage libraries.78
Thiazolidinedione aldol
Thiazolidinedione compounds have been described as acting
as donor compounds in uncatalysed aldol reactions.102 This
methodology has very recently been extended to peptide and
protein modification (Scheme 16).79 The ligation was demon-
strated on C-protected glyoxyl-dipeptides with a number of
simple thiazolidinediones bearing various functionality such
as alkyne, azide and short chain PEG moieties. Additionally,
modification of glyoxyl-myoglobin can be achieved in a
5 : 1 pH 6.5 PB : t-BuOH solvent system with conversions of
66–83% observed within 3 hours at 37 °C ( judged by LC-MS
analysis, Table 1, entry 24). In all cases, high concentrations of
thiazolidinedione reagent were utilised (1000 molar equi-
valents with respect to glyoxyl-myoglobin concentration). UV-vis
analysis, CD analysis, and analysis of the proteins ability to
store and release oxygen were performed on unmodified and
modified myoglobin samples, confirming that the tertiary
structure of the protein was unaﬀected.79 Observed reaction
kinetics for the Thiazolidinedione aldol ligation were 0.0078
M−1 s−1 (Table 1, entry 23),79 which are comparable to that of
uncatalysed hydrazone and oxime ligations at pH 7.0–7.4.66,70
Trapped-Knoevenagel
A Knoevenagel condensation reaction between fGly peptides/
antibodies and compounds containing enolisable protons
has very recently been described (Scheme 17). In this ligation,
thiopyrazolone reagents are subjected to the fGly species to
aﬀord C–C linked tetrahydrothiopyranopyrazolone products.40
The reaction occurs via initial enone formation between the
aldehyde and thiopyrazolone, followed by intramolecular cycli-
sation through Michael-type addition of the thiol side chain
onto a transiently generated enone (for this reason, the lig-
ation is also referred to as a ‘trapped’ Knoevenagel ligation).
This ligation strategy proceeds at pH 7.0–7.2 and has been vali-
dated on benzyloxyacetaldehyde, benzaldehyde and fGly func-
tionalised peptides. The Trapped-Knoevenagel ligation has
also been explored in the synthesis of ADCs through the
tagging of fGly functionalised Herceptin with thiopyrazole-
functionalised maytansine; ligation of these species exhibits
a rate constant of 0.387 M−1 s−1 (Table 1, entry 25),
and the resulting constructs display both in vitro and in vivo
cytotoxicity.40
IV. Conclusions and outlooks
Over the past 25 years (and particularly within the last decade),
the site-selective modification of aldehyde handles incorpor-
ated into proteins has been at the forefront of the field of
chemical biology, with aldehydes proving to be a highly versa-
tile method of generating homogenous protein conjugates
Scheme 16 Outline of modiﬁcation of glyoxyl-myoglobin with
thiazolidinediones.
Scheme 17 Outline of the Trapped-Knoevenagel ligation on fGly-
tagged Herceptin.
Scheme 15 Outline of 2-amino benzamidoxime ligation on M13 phage
bearing glyoxyl-peptides.
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with wide ranging applications. Although the aldehyde (and by
extension, ketone) handle is sometimes referred to as a ‘bio-
restricted’ (due to diﬃculties in achieving site-selective modifi-
cation in biological environments where other reactive
carbonyls such as cofactors are present, or where acidic con-
ditions cannot be used),103,104 this innovation drive has also
lead to the development of new methods for labelling
protein aldehyde which are functional in complex biological
mixtures.41,48
As the number of methods available for both incorporation
and modification of protein aldehydes continues to increase, it
is therefore beneficial to consider potential areas for develop-
ment in the field to further augment the existing ‘toolbox’.
Firstly it would be advantageous to establish a hierarchy of pri-
vileged reaction partners which would allow non-specialists in
the field to easily determine which ligation strategy is most
appropriate for a specific experimental requirement i.e. which
ligations aﬀord either highest conversions (most important if
pure protein conjugate is required), or fastest conversions
(more important in in vivo studies) with each individual alde-
hyde partner e.g. glyoxyl, fGly, aryl aldehydes etc. To unequi-
vocally establish these formulations, it is necessary for ligations
to be trialled experimentally with a number of diverse alde-
hyde handles. Although oxime/hydrazine ligations have been
widely deployed (see Table 1, entries 1–7), many other ligation
strategies in the literature have, as yet, only been described for
one type of aldehyde – typically a glyoxyl functionality (see
Scheme 18), which currently makes eﬀective comparison and
profiling of the merits of each individual method a diﬃcult
proposition. On a related note, it is also important to continue
on-going screening eﬀorts to accelerate the rate of many of the
ligations described. Although, the traditional hydrazone/oxime
ligation is considered slow in comparison to alternative ‘click’
based bioorthogonal conjugation methods, especially at
neutral pH, recent aniline catalyst explorations and rate profil-
ing with aminooxy/hydrazine partners have facilitated signifi-
cant rate enhancements, vastly increasing the general
applicability of the ligation at neutral pH. Similarly, extensive
screening of buﬀer conditions and reaction probe structure (as
seen in the Pictet Spengler, SPANC and ABAO ligations) has
also lead to increases in reaction rate and eﬃciency.
It is also essential that eﬀorts to explore new strategies for
forming C–C bonds in aldehyde ligations continue. Although
the eﬃciency of hydrazone/oxime ligations with diverse part-
ners has justifiably established their position as the premier
method for modifying protein aldehydes, the CvN bond
formed can be hydrolytically unstable in biological conditions.
This is not the case for the C–C bond formed during other
ligations described within this review, such as the Pictet Spen-
gler series. These ligations can potentially generate more
stable protein conjugates with longer half-lives, which poten-
tially have more general biotechnological and translational
applicability, as highlighted by recent syntheses of antibody-
drug conjugates using Hydrazino-iso-Pictet Spengler ligations.105
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